Johnson & Johnson (JNJ) saw its shares close nearly 4% higher, overcoming a trimmed profit forecast and regulatory challenges. The company reported better-than-expected quarterly earnings of $2.67 per share, beating analyst estimates by 11 cents, while its pharmaceutical unit continues to excel with support from blockbuster drugs. However, ongoing headwinds, including pricing pressures and litigation costs, pose challenges as the firm navigates a mixed financial landscape.
“Johnson&Johnson · closed · nearly 4% higher · despite trimming its profit forecast”
“Johnson&Johnson · erased early losses · increase · 3%”
“Johnson & Johnson · has · stock performance · +7.4%”
“Johnson & Johnson · is · performing well · supported by blockbuster drugs”
“Johnson & Johnson · has · blockbuster drugs · Darzalex and Stelara”
“Johnson & Johnson · has · new drugs contributing to sales · Erleada and Tremfya”
“Johnson & Johnson MedTech unit · is · recovering · in Q1”
“Johnson & Johnson · is making · progress · with its pipeline and line extensions”
“Johnson & Johnson · faces · headwinds · like generic competition and pricing pressure”
“Johnson & Johnson · has taken · steps · to resolve its talc and opioid litigation”
“Johnson & Johnson · has · stock performance · +7.4%”
“Johnson & Johnson (JNJ) · cut · its full-year profit forecast”